Tolerability and benefit of a tetramethoxyluteolin-containing skin lotion

International Journal of Immunopathology and Pharmacology

Volumn 30, Issue 2, 2017, Pages 146-151

  Theoharides, Theoharis C ^a   Stewart, Julia M ^a   Tsilioni, Irene ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

allergy; atopic dermatitis; inflammation; luteolin; mast cells; psoriasis; tetramethoxyluteolin

Indexed keywords

ANTIALLERGIC AGENT; LUTEOLIN; TETRAMETHOXYLUTEOLIN; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CHAMOMILE; FLAVONE DERIVATIVE; PLANT EXTRACT; SKIN CREAM;

ADOLESCENT; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; FRUIT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOCAL THERAPY; LOTION; MALE; MAST CELL; MAST CELL ACTIVATION SYNDROME; MASTOCYTOSIS; MIDDLE AGED; OLIVE; PRIORITY JOURNAL; PSORIASIS; QUESTIONNAIRE; SKIN; SKIN IRRITATION; SKIN LOTION; SKIN SENSITIVITY; HONEY; OLIVE TREE; ORIGANUM; PILOT STUDY; TOPICAL DRUG ADMINISTRATION; TOXICITY TESTING; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; CHAMOMILE; DERMATITIS, ATOPIC; FEMALE; FLAVONES; FRUIT; HONEY; HUMANS; MALE; MIDDLE AGED; OLEA; ORIGANUM; PILOT PROJECTS; PLANT EXTRACTS; PSORIASIS; SKIN CREAM; SKIN IRRITANCY TESTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85020376451     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/0394632017707610     Document Type: Article

References (34)

1. Theoharides TC, (2013) Atopic conditions in search of pathogenesis and therapy. Clinical Therapeutics 35 (5): 544-547.
2. Heratizadeh A, (2016) Atopic dermatitis: New evidence on the role of allergic inflammation. Current Opinion in Allergy and Clinical Immunology 16 (5): 458-464.
3. Theoharides TC, (2016) Skin mast cells: Are we missing the forest for the trees? Experimental Dermatology 25 (6): 422-423.
4. Theoharides TC, Valent P, Akin C, (2015) Mast cells, mastocytosis, and related disorders. The New England Journal of Medicine 373 (2): 163-172.
5. Finn DF, Walsh JJ, (2013) Twenty-first century mast cell stabilizers. British Journal of Pharmacology 170 (1): 23-37.
6. Theoharides TC, Sieghart W, Greengard P, et al. (1980) Antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein. Science 207 (4426): 80-82.
7. Oka T, Kalesnikoff J, Starkl P, et al. (2012) Evidence questioning cromolyn's effectiveness and selectivity as a "mast cell stabilizer" in mice. Laboratory Investigation 92 (10): 1472-1482.
8. Weng Z, Zhang B, Asadi S, et al. (2012) Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PLoS ONE 7 (3): e33805.
9. Cury MJ, Martins C, Aoki V, et al.Topical tacrolimus for atopic dermatitis. Cochrane Database of Systematic Reviews 7: CD009864.
10. Vieira Dos SR, Magerl M, Martus P, et al.Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. British Journal of Dermatology 162 (3): 674-676.
11. Viola P, Viola M, (2009) Virgin olive oil as a fundamental nutritional component and skin protector. Clinics in Dermatology 27 (2): 159-165.
12. Owen RW, Giacosa A, Hull WE, et al. (2000) Olive-oil consumption and health: The possible role of antioxidants. The Lancet: Oncology 1: 107-112.
13. Kishikawa A, Ashour A, Zhu Q, et al. (2015) Multiple biological effects of olive oil by-products such as leaves, stems, flowers, olive milled waste, fruit pulp, and seeds of the olive plant on skin. Phytotherapy Research 29 (6): 877-886.
14. Middleton EJ, Kandaswami C, Theoharides TC, (2000) The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease and cancer. Pharmacological Review 52 (4): 673-751.
15. Walle T, (2007) Methylation of dietary flavones greatly improves their hepatic metabolic stability and intestinal absorption. Molecular Pharmaceutics 4 (6): 826-832.
16. Wei G, Hwang L, Tsai C, (2014) Absolute bioavailability, pharmacokinetics and excretion of 5,7,3′4′ -tetramethoxyflavone in rats. Journal of Functional Foods 7: 136-141.
17. Weng Z, Patel AB, Panagiotidou S, et al. (2015) The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. Journal of Allergy and Clinical Immunology 135 (4): 1044-1052.
18. Kimata M, Shichijo M, Miura T, et al. (2000) Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clinical and Experimental Allergy 30: 501-508.
19. Jeon IH, Kim HS, Kang HJ, et al. (2014) Anti-inflammatory and antipruritic effects of luteolin from Perilla (P. frutescens L.) leaves. Molecules 19 (6): 6941-6951.
20. Weng Z, Patel AB, Vasiadi M, et al. (2014) Luteolin inhibits human keratinocyte activation and decreases NF-kappaB induction that is increased in psoriatic skin. PLoS ONE 9 (2): e90739.
21. Papaliodis D, Boucher W, Kempuraj D, et al. (2008) The flavonoid luteolin inhibits niacin-induced flush. British Journal of Pharmacology 153: 1382-1387.
22. Palombo R, Savini I, Avigliano L, et al. (2016) Luteolin-7-glucoside inhibits IL-22/STAT3 pathway, reducing proliferation, acanthosis, and inflammation in keratinocytes and in mouse psoriatic model. Cell Death & Disease 7 (8): e2344.
23. Kempuraj D, Madhappan B, Christodoulou S, et al. (2005) Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. British Journal of Pharmacology 145: 934-944.
24. Dirscherl K, Karlstetter M, Ebert S, et al. (2010) Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. Journal of Neuro-inflammation 7: 3.
25. Jang S, Kelley KW, Johnson RW, (2008) Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proceedings of the National Academy of Sciences of the United States of America 105 (21): 7534-7539.
26. Chen HQ, Jin ZY, Wang XJ, et al. (2008) Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation. Neuroscience Letters 448 (2): 175-179.
27. Slopen N, Glynn RJ, Buring JE, et al. (2012) Job strain, job insecurity, and incident cardiovascular disease in the Women's Health Study: Results from a 10-year prospective study. PLoS ONE 7 (7): e40512.
28. Theoharides TC, Asadi S, Panagiotidou S, (2012) A case series of a luteolin formulation (NeuroProtek®) in children with autism spectrum disorders. International Journal of Immunopathology and Pharmacology 25 (2): 317-323.
29. Theoharides TC, Tsilioni I, Patel AB, et al. (2016) Atopic diseases and inflammation of the brain in the pathogenesis of autism spectrum disorders. Translational Psychiatry 6 (6): e844.
30. Patel AB, Tsilioni I, Leeman SE, et al. (2016) Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism. Proceedings of the National Academy of Sciences of the United States of America. Epub ahead of print 23. DOI: 10.1073/pnas.1604992113.
31. Yang XW, Li YH, Zhang H, et al. (2016) Safflower Yellow regulates microglial polarization and inhibits inflammatory response in LPS-stimulated Bv2 cells. International Journal of Immunopathology and Pharmacology 29 (1): 54-64.
32. Harwood M, nielewska-Nikiel B, Borzelleca JF, et al.A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food and Chemical Toxicology 45 (11): 2179-2205.
33. Theoharides TC, Conti P, Economu M, (2014) Brain inflammation, neuropsychiatric disorders, and immunoendocrine effects of luteolin. Journal of Clinical Psychopharmacology 34 (2): 187-189.
34. Jones QR, Warford J, Rupasinghe HP, et al. (2012) Target-based selection of flavonoids for neurodegenerative disorders. Trends in Pharmacological Sciences 33 (11): 602-610.